Annual General Meeting

• Notice of Annual General Meeting October 2024

• Notice of Annual General Meeting November 2023
• Notice of Annual General Meeting November 2022
• Notice of Annual General Meeting November 2021
• Notice of Annual General Meeting November 2020
• Notice of Annual General Meeting September 2019
• Notice of Annual General Meeting October 2018
• Notice of Annual General Meeting October 2017
• Notice of Annual General Meeting October 2016
• Notice of Annual General Meeting October 2015

Presentations

• Scancell Year End Results Presentation 2024 
• Scancell Interim Results Presentation January 2024
• AGM Presentation 2023
• Positive Data for SCIB1, 19th September 2023
• AGM Presentation 2022
• AGM Presentation 2021
• AGM Presentation 2020
• Proactive Investors Presentation, 27th August 2020 (video link)
• Scancell Presentation to LSX World Congress February 2020
• AGM Presentation 2019
• Shares Magazine Investor Presentation July 2019 (video link)
• Shares Magazine Investor Presentation July 2019
• Scancell Proactive Investors Presentation April 2019
• Scancell China BioCentury Presentation November 2018
• Scancell LSX Presentation November 2018
• Scancell Proactive Investors Presentation November 2018
• AGM Presentation 2018
• Scancell Presentation February 2018
• AGM Presentation 2017
• AGM Presentation 2016

Trinity Delta Reports

• Heading into important 2024 clinical catalysts
• Successful upsized placing raises over £10m
• SCIB1 SCOPE study shows a striking 82% ORR
• Upcoming SCIB1 data could provide first proof of concept
• Modi-1 successful in first part of Phase I/II trial
• Scancell, a leader in antibody and vaccine technology platforms
• A fresh impetus in delivering immune-oncology vaccines
• COVIDITY programme to start Phase I in H221
• H121 results highlight shift to delivery and execution January 2021
• Redmile funding releases the brakes 17 November 2020
• Material fund raise means clinical progress in sight
• COVID 2nd generation vaccine opportunity is all upside May 2020
• Reasons to be cheerful May 2020
• Interim results show encouraging progress January 2020
• A sweet source of financing September 2019
• SCIB1 Phase II study starts in UK August 2019
• Ground prepared for an important period July 2019
• Vulpes investment brings £3.88m in new funds June 2019
• SCIB2 to use new nanoparticle formulation May 2019
• Phase II melanoma study with SCIB1 to start in Q219 April 2019
• Interim results show progress being maintained January 2019
• Missing out on CRUK Grand Challenge January 2019
• Opening new pathways in immuno-oncology November 2018

Hardman & Co Reports

• View February 2018 Report
• View September 2016 Report

Circulars

• Scancell Circular 23rd July 2020
• Scancell Circular 19th April 2018
• Scancell Circular 11th March 2016
• Scancell Circular 9th July 2013
• Scancell Circular 30th June 2011

Memorandum of Association

• Memorandum of Association

Certificate of incorporation

• Certification of incorporation

Current Articles of Association

• Current Articles of Association

Admission Document

• Admission Document